Digital Transformation in the Pharmaceuticals Industry—Companies-to-Action, 2018
Value-based Care, Patient Data Digitization, and Collaborative Technology Deployment Offer Investment Opportunities
  • he pharmaceutical industry today is in a state of flux as it tries to maintain a delicate balance between the need for novel blockbuster drugs and the need for improved operational efficiencies in an increasingly competitive market space. As healthcare is becoming increasingly democratized, patients are emerging as key decision makers—digitally enabled by the entry of non-traditional tech companies such as Apple, Facebook, and Google—pushing pharmaceutical companies to go beyond-the-pill. However, in the midst of this chaos, there are pioneering companies offering solutions that apply cutting-edge digital technologies such as AI, Big Data and analytics, cloud, mobile, blockchain, and Internet of Things (IoT) to build digital convergence across the pharmaceutical value chain, covering R&D, manufacturing and operations, marketing, and patient connect. This Companies to Action (C2A) analysis puts the spotlight on such game-changing, tech-enabled participants and how they are altering the status-quo by highlighting novel monetization models and strategic investment opportunities.

    Click image to view it in full size

    • Get Access to Complimentary Intelligence
    • * indicates mandatory fields
    • Firstname*
    • Lastname*
    • Company*
    • Job Title*
    • Business Phone*
    • Job Role*
    • Business Email*
    • Industry
    • Are you in the media?*
    • We'd love to send you exclusive offers and the latest info from Frost & Sullivan in the areas of:
    • Please tick the boxes below to tell us all the ways you would prefer to hear from us:
    • Frost & Sullivan values your privacy and we will never share or sell your personal information to third parties. Please visit our Privacy Policy.